- Home
- RMNI vs MGNX Comparison
RMNI vs MGNX Comparison
Compare RMNI & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMNI
- MGNX
- Stock Information
- Founded
- RMNI 2005
- MGNX 2000
- Country
- RMNI United States
- MGNX United States
- Employees
- RMNI N/A
- MGNX N/A
- Industry
- RMNI Business Services
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- RMNI Consumer Discretionary
- MGNX Health Care
- Exchange
- RMNI Nasdaq
- MGNX Nasdaq
- Market Cap
- RMNI 163.3M
- MGNX 263.1M
- IPO Year
- RMNI N/A
- MGNX 2013
- Fundamental
- Price
- RMNI $1.76
- MGNX $3.25
- Analyst Decision
- RMNI Hold
- MGNX Buy
- Analyst Count
- RMNI 1
- MGNX 12
- Target Price
- RMNI N/A
- MGNX $8.89
- AVG Volume (30 Days)
- RMNI 179.9K
- MGNX 667.7K
- Earning Date
- RMNI 10-30-2024
- MGNX 11-04-2024
- Dividend Yield
- RMNI N/A
- MGNX N/A
- EPS Growth
- RMNI 340.37
- MGNX N/A
- EPS
- RMNI 0.18
- MGNX N/A
- Revenue
- RMNI $429,431,000.00
- MGNX $41,018,000.00
- Revenue This Year
- RMNI N/A
- MGNX $105.96
- Revenue Next Year
- RMNI N/A
- MGNX N/A
- P/E Ratio
- RMNI $9.74
- MGNX N/A
- Revenue Growth
- RMNI 1.64
- MGNX N/A
- 52 Week Low
- RMNI $1.55
- MGNX $3.14
- 52 Week High
- RMNI $3.44
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- RMNI 39.84
- MGNX 38.45
- Support Level
- RMNI $1.70
- MGNX $3.20
- Resistance Level
- RMNI $1.96
- MGNX $3.60
- Average True Range (ATR)
- RMNI 0.10
- MGNX 0.20
- MACD
- RMNI 0.04
- MGNX 0.04
- Stochastic Oscillator
- RMNI 33.33
- MGNX 11.65
About RMNI Rimini Street Inc. (DE)
Rimini Street Inc is a provider of enterprise software support products and services and a third-party support provider for Oracle and SAP software products based in the United States. The company offers solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. Some of its products include Oracle E-business suite, Oracle Database, Peoplesoft, SAP business suite, and others. The company derives maximum revenue from United states.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 × CTLA-4), Tebotelimab (PD-1 × LAG-3), MGD024 (CD123 × CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV × CD3).